Recent investigations have centered on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and DA communication. While GIP agonists are widely employed for addressing type 2 diabetes, their unexpected consequences on reward circuits, specifically governed by DA systems, are attracting si